



### One-line Pitch:

We create resistance-suppressing combinations of FDA approved antibiotics.

### Business Summary:

Viosera targets underserved infectious disease markets. We leverage existing FDA-approved and off-patent drugs, and combine them in ways that enhance their effectiveness against the most deadly infections. We leverage the safety, chemical, manufacturing, and quality control data and practices already developed for the individual drugs in our combinations to expedite pre-clinical and clinical trials. We can take new antibiotic therapies to market faster and at lower cost and risk.


### First Target Market: Methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections

**81,000** patients, **11,000** deaths (US annual), **171,200** patients, **21,000** deaths (EU annual)

The 3 current MRSA bloodstream infection therapies are ineffective with each (vancomycin, daptomycin, televancin) having less than 50% clinical success. This represents more than **\$2 billion** in U.S. healthcare costs.

### Product and Competitive advantage: VT1-MRSA bloodstream infection therapy

VT1 is an IV antibiotic composed of three safe, off-patent FDA approved antibiotics, that cannot be formulated by hospitals or physicians. When resistance arises to any one of VT1's sub-components it makes the remaining components more effective at clearing the MRSA infection. VT1 is 100% effective in mouse MRSA models. Our combination is protected by I.P. filings in the U.S., Europe, and Asia. Polsinelli and Global Patent Group have given positive patentability and freedom to operate reports. We have formulated VT1, asses PK in model systems, and performed toxicity testing. We have formed a supply chain and are evaluating clinical trial sites. We are reviewing proposals for leading a pre-IND meeting with the FDA.



VT1 stops resistance evolution and kills MRSA

A novel ratio of approved drugs

Qualifies for expedited approval

Gonzales et al., 2015, Nature Chemical Biology

### Management Team:

**CEO, Co-Founder – Nicholas Goldner:** Consulted for The Balsa Group and an Idea supporter the Balsa Foundation since its inception. He is receiving his PhD from Washington University.

**COO, Co-Founder – Christopher Bulow:** Worked with Griffin Technology and Vanderbilt University Medical Center on patent licensing, consumer research, and market strategy development. He is receiving his PhD from Washington University.

**CFO – Stephen Trampe:** Serial entrepreneur who has brought over 20 startup companies to exit with cumulative sales of > \$1 billion.

**CSO – Aki Kau, PhD:** Expert in microbial pathogenesis with over 14 years of research experience.

**Chairman of the Scientific Advisory Board, Co-Founder – Gautam Dantas, PhD:** Associate Professor at Washington University and a world leader of antibiotic resistance research.

**FDA Regulatory Director – Al Edwards, PharmD:** 45+ year regulatory expert who served as Director of Global Regulatory Affairs Operations at Takeda Global Research & Development Center.

**Director of Manufacturing – Felix Martinson, MBA:** 15-year pharmaceutical quality assurance and manufacturing expert. He serves as the Quality Director at Mallinckrodt Pharmaceuticals.